Clinical Trials
3 trialsNCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT04149444 2020-06-11
TACTIC
AHS Cancer Control Alberta
Phase 2 Withdrawn
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn